1-5 of 5
Vinayakumar Siragam, PhD
Close
Sort by
Journal Articles

IVIg-Primed Splenocytes Ameliorate Murine ITP in an MHC Class II-Unrestricted Manner.

Andrew R. Crow, BRT, Vinayakumar Siragam, PhD, John Freedman, MD, Alan H. Lazarus, PhD
Journal: Blood
Blood (2007) 110 (11): 102.
https://doi.org/10.1182/blood.V110.11.102.102
Published: 2007
Journal Articles

IVIg-Primed Leukocytes Offer Longer Protection in the Amelioration of ITP Than IVIg.

Andrew R. Crow, BSc, Davor Brinc, BSc, Vinayakumar Siragam, PhD, John Freedman, MD, Alan H. Lazarus, PhD
Journal: Blood
Blood (2006) 108 (11): 703.
https://doi.org/10.1182/blood.V108.11.703.703
Published: 2006
Journal Articles

Monoclonal IgG Specific for the CD44 Antigen Mimics the Action of IVIg in the Amelioration of ITP.

Seng Song, MD, Andrew R. Crow, MSc, Vinayakumar Siragam, PhD, John Freedman, MD, Alan Lazarus, PhD
Journal: Blood
Blood (2005) 106 (11): 2170.
https://doi.org/10.1182/blood.V106.11.2170.2170
Published: 2005
Journal Articles

Inhibition of Immune Thrombocytopenic Purpura (ITP) by an Orally Bioavailable Inhibitor of Syk Kinase Activity.

Andrew R. Crow, BSc, Vinayakumar Siragam, PhD, John Freedman, MD, Elliott B. Grossbard, MD, Esteban S. Masuda, PhD, Polly Pine, PhD, Alan H. Lazarus, PhD
Journal: Blood
Blood (2005) 106 (11): 2165.
https://doi.org/10.1182/blood.V106.11.2165.2165
Published: 2005
Journal Articles

Can IVIg Preparations with Specificity for Soluble Antigens Mimic the Therapeutic Effects of IVIg in the Treatment of Immune Thrombocytopenia?.

Vinayakumar Siragam, PhD, Davor Brinc, BSc, Andrew R. Crow, BSc, Seng Song, MD, John Freedman, MD, Alan H. Lazarus, PhD.
Journal: Blood
Blood (2004) 104 (11): 2073.
https://doi.org/10.1182/blood.V104.11.2073.2073
Published: 2004